Volume 29, Number 10—October 2023
Dispatch
Estimated Costs of 4-Month Pulmonary Tuberculosis Treatment Regimen, United States
Carla A. Winston
, Suzanne M. Marks, and Wendy Carr
, Suzanne M. Marks, and Wendy Carr
Table
Input characteristics and direct treatment costs estimated for pulmonary drug-susceptible TB treatment, United States*
| Characteristic |
4-month regimen |
6-month regimen |
|||
|---|---|---|---|---|---|
| Intensive phase |
Continuation phase |
Intensive phase |
Continuation phase |
||
| Time (doses) |
8 wks (56 doses) |
9 wks (63 doses) |
8 wks (56 doses) |
18 wks (126 doses) |
|
| Anti-TB medications |
Isoniazid 300 mg, rifapentine 1,200 mg, pyrazinamide 2,000 mg, moxifloxacin 400 mg |
Isoniazid 300 mg, rifapentine 1,200 mg, moxifloxacin 400 mg |
Isoniazid 300 mg, rifampin 600 mg, pyrazinamide 2,000 mg, ethambutol 1,600 mg |
Isoniazid 300 mg, rifampin 600 mg |
|
| No. daily pills† |
15 |
11 |
12 |
4 |
|
| No. DOT clinic visits‡ |
40 |
45 |
40 |
90 |
|
| Costs§ | |||||
| Examination | 370 | 402 | |||
| Clinic supply | 74 | 80 | |||
| Medication | 3,023 | 1,546 | |||
| DOT | 2,354 | 3,600 | |||
| Subtotal outpatient costs | 5,820 | 5,628 | |||
| Subtotal inpatient costs¶ | 17,432 | 17,432 | |||
| Total estimated direct treatment costs | 23,252 |
23,060 |
|||
*DOT, directly observed therapy; TB, tuberculosis. †Pill count assumed anti-TB medications plus 1 daily pyridoxine (vitamin B6) tablet for persons taking isoniazid. ‡DOT administered 5 of 7 weekly doses throughout treatment. §In 2021 US dollars. ¶Inpatient costs assumed equivalent across regimens because TB outcomes and adverse events were similar according to clinical trial data.
Page created: August 02, 2023
Page updated: September 20, 2023
Page reviewed: September 20, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.